U.S. Physical Therapy, Inc. (USPH)

The immediate outlook is mixed, caught between a defensive setup and a potential bounce. While the statistical forecast leans slightly negative, the recent price action shows resilience, climbing from the mid-$60s to the low-$70s over the last two weeks. However, the heavy put activity at lower strikes suggests the market remains wary of further declines, likely due to the lingering pressure from the previous two years of double-digit annual drops. Long-term, the business fundamentals are the primary driver here. Despite the recent price underperformance, the company is executing its roll-up strategy effectively, evidenced by recent acquisitions and expansion into new states. Revenue growth is positive at nearly 8%, and the forward P/E of roughly 21x implies the market expects a significant earnings multiple expansion to justify the current valuation. The balance sheet is manageable, though debt levels are notable. This disconnect between deteriorating stock price and improving operational metrics creates a compelling case for a patient buyer, provided the multi-year downtrend doesn't accelerate again.